This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Gourlay, T Search for Related Content PubMed PubMed Citation Articles by Gourlay, T Social Bookmarking                   What's this?

Biomaterial development for cardiopulmonary bypass

Cardiothoracic Surgery, National Heart and Lung Institute, Imperial College School of Medicine at Hammersmith Campus, London

Cardiopulmonary bypass (CPB) is dependent on materials foreign to the patient for its successful application. When blood comes into contact with these so-called biomaterials, an inappropriate inflammatory response, which can be life-threatening in some patients, may develop. The reason for this inappropriate activation of host defence mechanisms is not entirely clear, however a number of strategies have evolved over the years to minimize this unwanted sequelae of CPB. These strategies include surface coating of the materials of the circuit, using new materials thought to improve biocompatibility, and using a number of pharmacological interventions designed to suppress the inflammatory response. Recently, there has been some evidence which indicates that the plasticizer employed in the polyvinyl chloride (PVC) tubing of the CPB circuit may play a part in the development of the inflammatory response. The work described in this paper tends to support this thesis. These studies showed that by washing the plasticizer from the surface of the PVC tubing, the biocompatibility, as reflected in the upregulation of CD11b on the surface of neutrophils, was enhanced. Furthermore, the use of non-plasticized substitutes for PVC had a similar effect. The benefit from removing the plasticizer was similar to that gained from surface coating with heparin, one of the conventional approaches to reducing the inflammatory response to CPB.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				A. E. Asberg and V. Videm Neutrophil dysfunction after biomaterial contact in an in vitro model of cardiopulmonary bypass Eur. J. Cardiothorac. Surg., November 1, 2006; 30(5): 744 - 748. [Abstract] [Full Text] [PDF]

				K. A Samolyk, S. R Beckmann, and R. C Bissinger A new practical technique to reduce allogeneic blood exposure and hospital costs while preserving clotting factors after cardiopulmonary bypass: the Hemobag(R) Perfusion, December 1, 2005; 20(6): 343 - 349. [Abstract] [PDF]

				U. Abdel-Rahman, F. Ozaslan, P. S. Risteski, S. Martens, A. Moritz, A. Al Daraghmeh, H. Keller, and G. Wimmer-Greinecker Initial Experience With a Minimized Extracorporeal Bypass System: Is There a Clinical Benefit? Ann. Thorac. Surg., July 1, 2005; 80(1): 238 - 243. [Abstract] [Full Text] [PDF]

				K. T. Lappegard, M. Fung, G. Bergseth, J. Riesenfeld, J. D. Lambris, V. Videm, and T. E. Mollnes Effect of complement inhibition and heparin coating on artificial surface-induced leukocyte and platelet activation Ann. Thorac. Surg., March 1, 2004; 77(3): 932 - 941. [Abstract] [Full Text] [PDF]

				S. Gunaydin Clinical significance of coated extracorporeal circuits: a review of novel technologies Perfusion, January 1, 2004; 19(1_suppl): S33 - S41. [Abstract] [PDF]

				T Gourlay and P Connolly Does cardiopulmonary bypass still represent a good investment? The biomaterials perspective Perfusion, July 1, 2003; 18(4): 225 - 231. [Abstract] [PDF]

				T. Gourlay, I. Samartzis, and K. M Taylor The effect of haemodilution on blood/biomaterial contact-mediated CD11b expression on neutrophils: ex vivo studies Perfusion, March 1, 2003; 18(2): 87 - 93. [Abstract] [PDF]

				V. Vijay and K. McCusker Recent advances in biocompatible surface-modifying additives for cardiopulmonary bypass Perfusion, January 1, 2003; 18(1_suppl): 41 - 45. [PDF]